BioSpace News Archive

Manufacturers adapting unique strategies and collaborations with local integrators are creating wide opportunities for future prospects

Cathepsin B is an important mediator of inflammation and programmed cell death in individual cells. It has a role in inducing cell dissolution and recycling of cellular organelles.

Rising preference to the minimal invasive surgical treatment of stress urinary incontinence and the increasing cases amongst the older female population is a key factor propelling the market sales

The ongoing COVID-19 pandemic has emerged as one of the key drivers fueling the expansion of the video telemedicine market.

The growth of the global d-dimer testing market is ascribed to its high demand across the globe. Shortage of radiological interventions, cost effectiveness, and high accuracy is expected to bolster demand for d-dimer tests over the timeframe of analysis, from 2019 to 2029.

Evotec SE announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.

Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, has launched the next generation of its STARMAP® AI platform, v2.0.

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced its financial results for full year ended December 31, 2020, along with corporate progress.

4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products, a novel class of drug derived from the microbiome, is pleased to announce that its business combination with Longevity Acquisition Corporation, details of which were announced on 22 October 2020, has now become effective.

Masimo announced the results of a prospective study published in the Sri Lanka Journal of Child Health in which researchers in Colombo, Sri Lanka evaluated the efficacy of a pulse oximetry-based critical congenital heart disease newborn screening strategy using Masimo SET® pulse oximetry.1 The authors concluded that pulse oximetry is a “simple, noninvasive, cost-effective, feasible, and reliable test,” and found that it had higher CCHD screening sensitivity than physical exam.